- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen and welcome to the Insulet Corporation Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct the question-and-answer session, and instructions will follow at that time.

As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President of Investor Relations.

Deborah Gordon

Dilem. you, Thank thank quarter and joining for us Good earnings you call. third XXXX Insulet's afternoon, for With are; and call. and and today Wayde Bret me for Executive our Chief McMillan, Chief today Christensen, portion also Executive Jim Commercial Hollingshead, the Officer, Vice with Vice Q&A President Executive Chief is Officer; and Financial President President us Officer; our of on guidance XXXX this Investor available Both the our results and of of section website. the discussing call third the will and our XXXX replay release press quarter be Relations

adjusted is assessing measures with are our Before also to you interested could we explanation detailed namely uses this by discuss respect the to cautionary investors, current We’ll performance, performance, begin, measures inherent to operating align supplemental SEC call constant the what EBITDA excluding and believe we I as such would and with of other statements. in refer foreign differ of materially operating non-GAAP that Insulet of filings like inform These Please for course and analysts measures helpful of made period. certain of in measures the expectations. period statements a growth, parties our our effect performance as operating from revenue and revenue, exchange. adjusted forward-looking, which financial limitations our from management may be to margin, they during statements to currency the

call on Jim. basis constant to will growth the basis. revenue Additionally, a on unless exception otherwise stated, reported be turn that, regarding I’ll currency which percentage financial all with year-over-year will the With rate, be and over commentary a year-over-year dollar changes of

Jim Hollingshead

you Deb. for thank joining and Thanks, afternoon, us. Good

X we In starts year customer momentum a our milestones. achieved to outlook record a carrying strong and at and customer the revenue achieve X a market in execute was growth continues large increased incredible and marked the growth Omnipod finishing year and This from release and U.S. in revolutionary their again strong driven high delivered XXXX. XX% least advance full our continuation fantastic. delivery new part rate our level U.S. at quarter revenue third highest into strategic are entire start the for which finished. a from us We mission. team continues be progress. on growth we our to once insulin The The Omnipod Insulet We're decade. QX, by full our system. Podders helped in feedback U.S., We and performance, sustained U.S. of caregivers our remarkable several for new year-over-year course, revenue focused on far an global And notable automated our of

expand to platform. for addressable access work Omnipod to the as as our to well increase market total Omnipod continue We X

During the to Omnipod quarter, CE and secured we Mark. HX down X's indication expanded

XXX(k) what's I'll is we for The the from a further excited not We Building and clear both market for people share diabetes and in of insulin markets our our are international PODD accelerate and for our anticipated. coming is Omnipod a we indication we and to soon future our than also incredibly to in that, market. be continue moments. diabetes on a that especially new drive Demand in even X with market, growth to addressable a will U.S., for type type in X with the could about innovate more yet to to X. developed We Omnipod market. submit customers. have across expand It's the announce our commitment growth greater and few in all about DASH, come this basal-only more enthusiasm excited

new saw continues converting But product customers to customer higher users market breakthrough are also Omnipod at to and current seeing offering. a source of we than our rate Current own much MDI target the forecast as Omnipod users for launches, X previous is Podders demonstrating ahead a we significant in see of increases us. of core growing with Omnipod X conversions. are greatest that Our even be

of the as patient's algorithm range, is personalizes first of X clinical designed In those and Thousands significant our effectiveness Omnipod that been had specific increased from X. technologies. right works we are power AXc usage this back people coming and and strong converting then tubeless adopting each to the X new of Omnipod reports over we age is volumes the XX% of demand represented in It that competitive new tubed are users. from QX, of the with success. care starts starts all time an adult addition record release, This the customers advantages to U.S. it combination we X QX. The adaptive learns customers time pump the over delivering from in from who MDI, automatically box, We And customer winning and only of offers. range. our in and personalization, Omnipod reduction platform cases, and high and full consistent many also with system after compared us returning once AID market both low algorithm seeing In markedly And are pods. and that is comes of of XX% out seeing or two Because its customer of pediatric over validates groups. unique only X fueling achieved months Podders. to hypoglycemia. Omnipod It

saw We're excited management. and In pumps As are to gratified significantly a result, traditional coming Omnipod mix more QX, our is by competitive X from how is historical of due see those changing. XX-XX takeaways. diabetes our to XX-XX tubed split we estimated early progress transforming an and MDI

with their first system smart innovation, AID first AID that directly on other phone-controlled algorithm, simplicity, AID Omnipod will AID a We system. blood and and about patients glucose including predictive HCP demonstrating drive the on related a And of inspiring. management. We one to recently have said dramatic calculator, large is have this whom HCPs. Omnipod has in care improved markets. X, who pod-based for called incorporates she market, making system long XXX% number improvements that trends. the bolus underpenetrated X health Omnipod to the manage firsts. blood their system interaction and and compatible X to diabetes, patients believed and our levels, also their data outcomes, the market It's than X it stories clear in time, first range no their caregivers several "life-changing". it's And are they of glucose customers just be with They but our called first that This between superior discretion our easier heard are It's for system practitioner adoption access her been in the from offering amazed a the the in has more not our and experience is her offers true. diabetes any fully to plug the Omnipod system, first simplifying the the of patients time.

of the for To increased secured market contribution significant we of with Omnipod and made We U.S. gain expect XX% over additional traction X's X, to we accelerate initial our And growth coverage end, strides end for that we've expectations. covered by coverage. access. further commercial well as QX, ahead lives of Omnipod

market has particularly we that pressure onboarding our call experienced few also are response challenges The a head hitting have placed on. volumes. on incoming We incredible capabilities,

call slightly Additionally, initiated issue elevated correction managers month we the our we diabetes also battery for device DASH the voluntary identified in medical volumes. to last personal Omnipod response

Given controller this, we are our carefully in of Omnipod reviewing high ensure X to it meets the field safety expectations user early for the the process and on data satisfaction.

controller. related received calls inbound few a We the charging potential have a issue highlighting to

is if can Our X a expect single the to decide particular to Omnipod ultimately of we ongoing it swift you and and important to take aspect transparent. is us. work be experience Every action,

to and awareness are increase center call seeing access customer onboarding efforts. and We driving We're are investing through response resources, significantly our improved our times. growth and already

in model extremely and simple, Omnipod further leadership differentiated Both economic our a which a efficient make have to affordable, technology during We U.S. unique pharmacy and channel. access business times. position challenging the differentiates

access We for have our focused customers. on improving functional long

our than offer a $XX. $XX customers daily and injections, than proud X, outcomes the Consistent with As and co-pay both DASH cost Omnipod is our pay for to a through our multiple Omnipod result, to are pharmacy technology less U.S. average commitment to to channel at the expanded the vast quality life. access, less majority drive delivering also and continue month a we improved of similar of while

remain focused physicians our also on We model and to payers. provides the benefits

large far the access expensive and a model affordable makes and eliminating the for upfront superior make the plans since same offerings on easier channel of also costs pumps, lock-in At proposition traditional Our while every tube lengthy that for less customers average. insurance are is years common more We medical time, change payers. more expensive, it eliminate equipment durable in provides individuals periods. in value which couple pay-as-you-go especially with the U.S. those

the proposal, an same market, with now market if position space, novel this further comfortable the classic insulin approved, device, type a provide CGM and time, we're awareness also to key are in pleased with to CGM and tubeless and this would we are Omnipod type initiatives the X is in type our user leader with addition and taking proposal local our At expansion our Today, In step increases People the of the patients. increasingly access experience we that growing determination with an leadership on-body opportunity. space. are were well basal CGMs. innovation. strong are coverage We on Omnipod. drivers capitalize recent diabetes coverage becoming positioned with in we type a two offer unmatched another X rising, to X DASH This for

version into and on addressable to the three which with It injections. is adherence completely our FDA million should submit estimated in people daily or needles. the removing offerings regulatory to pod with leverages insulin others needs have alone. Omnipod specifically rate requires or their to adopt Pending people U.S. It in for product is begin in innovation channel, to the Pod other controller type to first-of-its-kind a greatly market the both our new we insulin of U.S. a total as evolve. for the for few Therapy X pod through It gets for fixed the weekly product hours. treatment to struggle creates phone pathway be and improve phobia U.S. use X designed product experience and a plan commercialization is early pathway, perfect wear type this pharmacy by XXXX. developed the access comfortable to basal-only entry clear we adherence may including patients with allows approximately creating them comfortable incredibly who and treat basal-only We auto Omnipod of clearance, continuous deliver to days. application user for basal-only simple rapid-acting This needle winning platform, to a patients The population. of unique plan a affordable The use no Omnipod therapy, insertion, and XX

to come revenue TAM is lives drive of with the expansion improving further upon Our expected leadership pod This type and the builds years while for innovation in basal-only X diabetes. market. to growth our position people

third During our represented with estimated of XX% X quarter, customer to starts. the new U.S. individuals an XX% type

X As market. expected, this adoption declining Omnipod driving given success X type in is the percentage our

base X confident our customer type advantage in that allow us X platform remain that we However, significant competitive expand represents X of both populations. the type to a and will Omnipod simplicity our the

for like only people reminder, AID a diabetes. with X currently indicated Omnipod use systems, As X is type for all

number confident adopting us, portfolio continue DASH type model of the and for to Serving strong. form population the and Omnipod remains product are innovative factor, X will the type customer adoption. However, X individuals is combination our with of a drive we priority very access

clinical our Another of advancing is area focus efforts.

with trial is We and begin benefits complete will of CGM. Omnipod France. on progressing results participants to track pump enrollment to believe non-AID X's in of Our We're to controlled XXX to the XX participants expect U.S. in Omnipod compared use demonstrate well. the X soon randomized enrollment up

our Omnipod position reimbursement to our in X We this will are secure markets. confident for and pricing strengthen broad international

mentioned, expanded indication I were receive age As down two excited for to we Omnipod to our X.

a segment X pediatric the and X Omnipod We our and families. feasibility type truly Based to happy Omnipod will children of XXXX. trial their we on study young these expect change positive X leader the pivotal share are begin Omnipod type X in that I'm confident are in results, X lives to a for

We data continue capabilities. AID robust as to pipeline on focus a and digital as our advance innovation building our with future well offerings

CGM X with our as to providing and product to offering ongoing integrate development choice is We GX to and work Omnipod customers. committed on DexCom's CGMs. also is integration remain iOS work Our of our building our Abbott's

innovation are will drive in priority investments we growth continued that and R&D value creation. strategic sustainable Our expect and fully a long-term

this in feeds. for integration global their One both digital partners, priorities with This diabetes management especially and data-driven Our and complete addressable area markets our feature real-time grow and CGM simplifies customers offers for important simplify are patients data products Omnipod caregivers. X physicians. management and usage our create diabetes clear: is to

be Looking for ahead, in physicians competitive use enhance our data advantages. patient experience, improve we on will strong to to a position further and workflows that build the

on At a deliver international building our CE receive while ensuring with same were we're and Omnipod This time, We to continuing local regulations. operations. our drive to globally. infrastructure developing experience X September. country-specific step premium Mark cloud-based protection path to X deliver our to compliance people Moving in the to reimbursement. focused necessary Omnipod We data launch to represents pleased the work plans Omnipod the for X remain major in needed

We enter first expect international to market in our mid-XXXX.

we our Omnipod planned X stage will Given out more XXXX. roll throughout broadly approach,

moat. our capabilities ramp supporting needs another Lastly, growth global customer and as Omnipod remain, headwinds but chain adoption competitive and support we are and macro-related base trajectory supply long-term the expanding of Global our global addressing manufacturing our X. the of serve

and Our capacity components team product needs. has of secured our forecasted built ahead

in While deliver uninterrupted for are impact increased our necessary customers. this that results products to they margins, cost

production to margin costs, the highest the continue all product continue will our of our we gross gross Although given margin will a expansion. term, long higher to quality U.S. confident to over sites combined are deliver headwind manufacturing the and be

notable key and are quality manufacturing driving Our that mission focused U.S. are achieved closing, productivity the improvements milestones In to across Wayde. capabilities strong. foundation is gain redundancy, again executing operational long-term and our team our growth. efficiency, to has commercial customers allowed year for once now sustainable our we facilities. our the everything us build and all learnings do, we over financial, With and finishing turn on of global at Insulet entire call center our will I strengthening and

Wayde McMillan

record-breaking Thanks, QX Jim. another marked quarter.

for team life-changing continues pharmacy the XX% X the to range, with momentum. We're execute total entering a includes a growth level. is Omnipod We and growth kits Omnipod to in as at almost from some their and new of with DASH XX%, Omnipod our XX% the Omnipod the driven Omnipod premium And the included ramp. at total for continues customer QX stocking basis, X of third of quarter the XX%. pod XX%. over quarter and the and in XXXX conversions quarter the point of high growth associated starts This starts combined compounding PDM Revenue comprised retail initial pharmacies. end on XXX On to option pharmacy global Omnipod, year Omnipod primarily Omnipod starter in X and finishing guidance XX% the diabetes. charge of customer a focused driven increasing million by Omnipod with generated in was no estimated revenue reported U.S. initial from DASH channel. Omnipod a a U.S. given X a customers both well proving revenue new high benefit $XX over quarter and in X from our at some driven to from and Omnipod This basis for new Growth volume Our an growing the above people be at starts, were range. first our compared year. as benefited benefit by by was customer of U.S. we strong revenue, foreign getting provide guidance total record the where refills finishing volume DASH Classic currency an contribution growth last was through channel. new headwind be we exceeding

our ongoing total was driven a currency X,XXX prior guidance to increased our X%, basis, by adoption, XX% almost range, reported a points headwind prior guide. approximately revenue On volume. channel AID was versus DASH XXX year, basis Omnipod pharmacy which competition. partially by over our Omnipod basis International foreign within volume the addition, of In increased U.S. point unfavorable offset

X-K included approximately to was including $XX XX.X%, impact points. currency representing of During revenue voluntary medical X% users. approximate the favorable the DASH units, benefit by higher, Omnipod million Gross recorded of ramp Cost in to additional attrition X,XXX was XXXX, XX of of charge primarily $XX foreign basis declined we estimated of utilization estimated longer QX, charge Delivery the high points device estimated. material and and $XX correction. driven costs at we year We X,XXX the expect to and Omnipod be an our reflects our million replacement related previously in global decrease no basis consistent reclaim filing. range. QX end is charge million point million mentioned. shipping or for included $XX the October global approximately this a X The revenue guidance within remained in a had any estimated Drug aggregate in margin the as our basis PDMs or This operating QX expenses

support mix X to year as than medical premium. investments QX adjusted including manufacturing device our increase were higher operating by XXX impacted by Omnipod growing growth. to voluntary channel, and to costs we costs costs were sales adjusted margin costs scale margin higher launch the in Omnipod basis The XX.X%, in as U.S. X year-over-year which higher These X gross primary work associated slightly our and device an associated ramp EBITDA and operating respectively. XX.X%, to ramping. offset expectations our metrics to was marketing, point business pharmacy decrease. the and demand Omnipod Both Adjusted U.S. partially given our Delivery such volume Drug correction, innovation in the of higher our of the our support were were expenses Operating QX, continued correction operations, were efforts, in drivers representing mix and QX Excluding the pipeline were a development expected with manufacturing medical and charge, for and XX.X% advance higher last of gross pressures higher exclude due margin expenses. costs than

million and cash million Turning with to cash facility. ended over liquidity. credit We $XX quarter the and under in full the our $XXX available

remains our business, to the growth financial our strengthen deliver and in further flexibility pipeline to strategically Our years strong offers invest for us position innovation and come.

Now turning to XXXX guidance.

are total our including year to to a total Omnipod XX%. company We full growth of revenue XX% growth raising to XX% of range XX%,

For our to U.S. are revenue Omnipod, to range XX%. we increasing XX%

of revenue driven and Omnipod and Omnipod Omnipod Omnipod both expect new Omnipod to as X our pay-as-you-go Classic We from as strong X volume business the DASH by primarily benefits growth conversions be and DASH to model. customer starts well increasing

For our mainly range headwinds. basis an exchange international competitive points. Omnipod, reported end of basis, we driven Growth X,XXX unfavorable guidance On by AID full of to low is partially are Omnipod impact estimate and adoption we of by a now year foreign raising approximately DASH the a XX% offset expect XX%. ongoing

now our XX% the Lastly, for decline of end Drug range guidance and raising Delivery, low full expect we year XX%. to are a of

XXXX as a As were levels elevated the result of pandemic. a reminder,

Turning gross to margin. XXXX

XX% benefit be by be impacted XX%. a our year-over-year Excluding channel. gross U.S. headwinds the basis, increasing of U.S. to lower On margin will delivery to we due costs and pharmacy margin of These revenue. of ramp, X the by correction, will ramping higher manufacturing with line in drug the voluntary product continue range Omnipod a offset to gross partially expect device volume expect associated we impact our the medical mix

the be years. these to stated, to previously of we many we gross of this for results similar we factors to impact as As year. And next our result, expect XXXX a couple expect margin

functions. our to including well our and launch Excluding due clinical expect efforts expanding the certain rise pipeline support marketing efforts, X sales of innovation as as Omnipod legal and and year-over-year the continue investments CEO to and scaling transition we to expenses in our costs, operating

to digits. innovation, scale operating to adjusted ongoing and margin support And and expectation international enterprise continue to expect margins reporting commercial markets X the XXXX, implementing as and the high associated and be to new operating continued gross to system, well XXXX. in for Omnipod U.S. costs to single launch our expect for functions the be given as with we We investments a the clinical, business in similar margin the

of commitment investments Our to we to beyond. expect in begin and to expansion and XXXX continues, bolus margin leverage this

Lastly, to capital we prior previous expenditures a increase. of now year expectation slight be level relatively with versus expect our

our revenue to Turning guidance. XXXX quarter fourth

approximately company total basis, including reported total expect XX% growth impact unfavorable we to points. a an Omnipod growth XX%. of XX% exchange of foreign to We XX%, of basis estimate On XXX

of U.S. For growth XX%. Omnipod, expect we to XX%

XX% expect XX%. points. growth of X,XXX On we For of basis, approximately unfavorable international a an exchange estimate Omnipod, we to basis impact foreign reported

full Insulet we delivering nominal QX exciting Finally, have and achieving sustainable year are In are Drug critical positioning expect growth. the be of fulfilled. majority as been further conclusion, the we times, Delivery These already long-term for to solid our revenue financial market our orders for innovation milestones the delivering performance please the We're With questions. milestones call on level the achieved focused high advancing of the to pipeline. Dalam, on our for mission. that, at and Omnipod we've progress a release execute continuing given open and recent made we've X,

Operator

the I Jeff comes And show from Johnson line from our Instructions] [Operator of Baird. question first

Jeff Johnson

we pause All here. focus fix lot are can be going should that any issue. seems it real guess expectations doesn't especially that maybe up good question But kind it on. that on. we you concerns brought focus XX come because of the I Omnipod we to bit charging tomorrow, think maybe right. and might now good risk from technologically, out congratulations have again. months you that then some X little issue early and and expectations "Hey, given I and and lot fix Jim. Great, we'll even could those is any now, ask grow a or things, up that's of a on on me maybe But on numbers the be figure seeing quarter. Yes, can a up that, Obviously, would of signs you you big be let numbers doesn't a start there back is have X months charging momentum up can XX for you Any have from high, have your this going issue, we have to or a maybe that new to to of stock maybe be -- that X XX all, should how Rxs say, to this at

understand risk Just level of kind charging issue. help us the of in this

Jim Hollingshead

Sure. Thanks, early It's days. really Jeff.

this looking couple complaints, start charging closely. is are. patient at to on So we're the let be the levels me dozen and we we're looking it's in X, able and going don't on number but yet for of of priority, the really we're at top a foremost the have of seeing what point, enough understand like data complaints of At it risk exactly And Omnipod complaints. first a what's us, to with safety And small absolutely the terms right?

And looking action investigate going going fully be I so have early to prepared said take if think going So in completely the we we're of kind transparent and customers, really obviously I with looking say, closely. be FDA, too it's fast. to really it the with to be we're our and right? to comments, at completely we're investors going we're We're transparent to any it. to And -- at as it. We're with

Operator

of Securities. Bank And the question America Steed I comes of from line from next Travis show our

Travis Steed

you there. little more people where Or sustainable can are dynamic on a trend to but think like coming that Do think We'll a this is said your patients the ask, XXXX. -- onetime lot you of really quarter. great hold? over about waiting then do think you're to more the way, you guess on to And Congrats you thousands. I just a for if on focus how this to pump I where the carries focus even think have is Omnipod to word things bolus more XX-XX color a a X? talking just

than OUS I I would may little below think the the Street's modeling growth. could do and better that? U.S. think a be XX% that

Jim Hollingshead

then add been Omnipod for general I'll Travis, market to Omnipod And offer. and It's team I'll X ask the waiting an say is that, appealing the I just that X. on maybe start color. has I'll some revolutionary. think such

You on long very for value competed but disposable prop, that guys factor time all wearable tubeless successfully. patch know the form pump, we a

we've automated delivery. Now insulin added

So the pump prop an pump. make choice the all with is channel, between in or it I'll access have reimbursement you the be going QX longer appealing to add And economics. today. and AID -- color. patients to want think a I no in that the don't less than patch that the they is that of access any and value and couple to if to But XXXX ask team the

Bret Christensen

Travis, it's Bret.

so That will have and make as has all you -- focus. of now Omnipod factor of come So it MDI. But that be form system, focus. don't an choice the get between don't It all. or said, superior about can continue been as they know, we of to our to XX% patients Jim our have AID new starts for years, talked from we've this XX-XX a where to split

in not if don't And We wanted from try know split it if of XX-XX, the offering those an system, factor be Omnipod. to chose preferred or really excited to of so there, yet settle if settle that AID changed We'll different finally XX/XX. us users choice there's to but than surprising somewhere but it's it's settles the to likely form that going see pump a to to in. a it's that Omnipod where -- to we're in bolus

conversions. coming it's really pump an But So these two exciting quarters. in in, we'll again, we're it settles development getting see the where that

Wayde McMillan

on is regions. different that the growth. Jim, And the up great. That's maker it just Bret If around AID rates question growth I could between difference the revenue really, said, up in the XXXX is pick as and shows

the a lot from got legacy we've as switches competitive and Jim as seeing remarks, increased well MDI then Bret our conversions product prepared of existing U.S., we just as with customers, momentum. and For Obviously, and demand said, in we're here. the had

So the a U.S. momentum of in lot

the think to Need some larger about some in not a in the momentum. about I for color do continue as way provide and couple color start DASH we're think dollar seen now -- range our volume XXXX. benefits We're should that for really here. of But that consistent. to think to this we'll U.S. XXXX to QX low February. we're the in markets said, to normalize right that lot should We that give then of think really XX% just the guidance. going thinking growth with call And that QX We'll in AID, at And we'll settle a carrying to us in about We without U.S. see in. we've is in well point grow here out QX. OUS growth you

bringing digits, midyear where rollout XXXX. to start are or Omnipod us double for We continue high That markets. that low But to it puts our to international bring X range. single will international is through digits

throughout both as we'll Bret getting it of more good just here be really highlighted. of confidence regions think I dynamic and some start would for be these monitoring now. QX And course, place to a in metrics, those

pretty changing So of get Omnipod with lot things X. we dynamically a

decline year as out and for would those do year. that So expect see to where XXXX. the this Delivery, just delivery same to we'll in did place guidance shake hit it At next as about we then put And monitor they drug this Drug our well. point,

would in this $XX $XX year-over-year. think million we're experiencing about year, of us reduction next year. that we kind a about the same that will million mid-$XX to That's what million put So range, and

provide us to as February next sets the official up color we'll on I year. we for But that So XXXX. some when guide said, get

Operator

the comes of line question JPMorgan. Robbie next our Marcus show from I from And

Robert Marcus

Yes. year. thanks the nonspecific quarter. guide very congrats great for next on And for a And Wayde,

will in that think I models good help place. get a

yet As give some lots they on could have patient, But hoping think was average macro and we the materially patients point your competitors it's out-of-pocket know just we or latest and monthly And the some are cost facing? disclosed us actual what about about for for I competitors, of I willing outside to you've some your business of you what if it Omnipod patient. basal? just and on average price very think and a talked the U.S. of in MDI is and cost disclose. the to headwinds And U.S. the versus is upfront headwinds macro model. for basal clearly the different different you as about different you of think don't a there headwinds the a

Bret Christensen

This Robbie, is Bret. take one. I that can

wanting it. X is years far to of the out And in allow sort effects lingering as an as a for team of we're field, model X.X. as can't COVID trends we've different. So model patients feeling are to we're business demand upgrade not feeling is excited started Omnipod The patients of start. is midst Omnipod our or macro a that the concerns. high. existing the business incredibly We're any affordable But spent recession-type that would of products say mentioned, any you inflationary I scalable, the from launch, in planning and and macro

$XX majority DASH below the X we with remained really of where that $X. and that Omnipod co-pays co-pays almost co-pays Omnipod exactly pharmacy low said very We've X less being all in got at on we've vast with so parity. channel mirror the than average, DASH the And price

pricing for with as very payers to and our added goes the got users. as contracts out-of-pocket You've similar far is

products, As and mentioned We'll I with our payers basal if reimbursement far about there co-pays. as question basal-only know now this asking with usage they'll DASH yet. Xs for type pod. as Xs some basal-only basal and not for DASH, DASH, We're insulin pump. for pod, But same axis. use out-of-pocket very be primarily and good they'll it reimbursement having discussions for intensive. the we It's exact X And type and that customize have a basal-only take is the that's and building that don't existing we've is and it do type you're

the next our come on we'll to of that more pod, So be building year with but product. basal-only plans reimbursement commercialization

Operator

I from from And William show next comes Blair. line our the question Margaret of Kaczor

Margaret Kaczor

Is a basal together? Type or even detail on to a that What have that closed-loop going trial to Or Is pump. maybe pump? Is going I in features wanted separate up, to to this specific a follow not? be look mechanical smart are the Is more is for be there? going this X in guess, pivotal to I it going pump? it the trial this we're the features?

Bret Christensen

Margaret, it's Bret.

Jim to use that anybody the pod. So about on a today about. the we've And for that we're complexity at basal-only access a lot pumps, product users excited like basal-only of a is wants start And DASH, it the was in what got some share complexity mentioned we and away not although more beginning will take excited there's pod. to we're call to built of basal-only for start of to some basal-only want that and usage.

a the is settings mentioned, with with very Jim won't key pod. of lot as controller. a basal-only So a around are because settings. That's no There it have complexity pumps

basal-only designed So the user, primary it's endocrinology, simplicity. that's for care, in focused on whether it's to be going and

we'll start what so more about its like. And share factor to looks form

how about, highlight product days. capture insulin, excited we we'll need just throughout And it's they can the the educating Jim what in they at to to life their avoid mentioned, X that an moment need want ejections progress the as type in be coming diabetes. so to they products Omnipod-like we're do future. are moment they start altogether to and As FDA submitting excited you on their injection all this in the patients But on we'll the do

Jim Hollingshead

Yes.

because used right into with our needs just as be leading will to. Bret earlier on then journey creates just our -- fact, get offer the will of as change, we'll be the thing and tag obviously same the further on using referred type insulin X them for TAM. with And I'll the patients product. And of patients Omnipod Bret's comments. a to much diabetes core upstream it a in In it the DASH, key offerings. Omnipod pod, to other Omnipod have their with we patients. platform much product, us for getting terms pathway That's the to growing for basal-only But We as now

basal in have patients. offerings. patients. progress And of they So the We're simplify therapy to natural use pathway will X their for it's dramatically other going and/or those experience a a great insulin customers for as those then type

Operator

Larry our Biegelsen Fargo. And of from question the from Wells next I show line comes

Larry Biegelsen

XXXX to do I ex XX% gave, congratulations why I to the a the I'm context you given? heard the trying that you in Wayde, correctly, do in in. Omnipod U.S., really that I items, wanted get think, about my how back of growth slower. XX% that you year, items for focus if on I echo on range $XX into QX, guiding you've the next expect little color reconcile, U.S. are onetime here. to QX, XX%, And And quarter we you I'll a in QX bit for given million, guidance if to strong more to put onetime the low I growth out, XX% QX we,

Wayde McMillan

Yes.

You bet, Larry.

just volume that we -- around volume this got Omnipod got X. with So starting additional we

as them order their kits when well people quarter. turns mentioned the Omnipod market of it first as timing X out we remarks, release months out in is in full the as percentage people As starter X, up in when on it of is getting start Omnipod X refill prepared we good only quarter. because ended the their had some for some of And -- a

And is then pharmacy to channels some So over us time as volume. had stock more that we happen retail some also to that retail stocking product. the start going and gave more additional

those are the drivers in additional X So volume of the quarter.

in very going whether high guide, to of the us of in next QX. how here play we're either lot of out. script. What or this to on the low continue think We've either that could and is Your will it closely. end their get people end these got push We're anticipating a month how that wait could scenarios a question to the we monitor many

middle next just month may the or their Some the people some script. immediately of people get may order in

have And continue dynamics to we're into to QX. if of volume watch this these some see going can and so

doing And monitor, happy well pharmacy innovation just in to At business things as We're doing. access a Omnipod as and changing the volume, we're of channel. get well the drive both lot lot very to a we all a awareness work a clinical as lot increasing around are so the dynamics with day, here. the doing end we're We're volume to the as of X. volume the

announce quarter of to us HX, lot down You drive this doing to volumes a here. saw things

little really the we're people in just But a to be we're place first a their a bit month the guide. X as this. so excited that the in take And front either QX to QX we'll months, or in and to Larry, monitor those the benefit whole you order. more somewhat QX be We -- little think talked get going the then, about first end longer And at take next by bit well. do offset should

on you very QX, are normalize QX you year. normalized basis QX. for benefits, a certainly for you're we then XXs last volume significantly had If right, quarter rate in as these strong comp. in much about we We to growth tougher And here low a look a forward then have

of So that Omnipod front the keep at we're X. we in And to then, course, end have of mind.

We're then for place that's in And QX. continue February really give us and really quarter changing of it, so out XXXX, to understand in think what start. I we good Again, We're trying We're low give some that QX is can mentioned, here XXs. see planning monitor give numbers. to another of official to And and to happen year, don't not but the a dollar of And which out business XXXX guiding. color, we're excited these next that. dynamics. we'll large going to we're some QX start the as law growing us want in just I of will in and the to guidance of that for key in front to get in growth settles the our whole

Operator

And Genuity. Caitlyn I next show from Cronin the Canaccord our from question line comes of

Caitlyn Cronin

was basal some that of one seen here. when gone made of more market, your moving The Kyle adding technology focus, commercial a have into more salespeople, in you diabetes meaningfully or other on commercial changes I the they partners mean, talk shift things This a X sort. of they've some specifically about type actually obviously, is I wanted into We've now. question a business to focus.

force make eventually think when next the and with should state type course about the to you'll of then XX the we to and bring the basal-only you AID the over the for how the maybe of respect wondered I market XX months X? Bret, investments an Just X now sales to type need

Bret Christensen

Kyle, thanks for the question.

you X So type access pharmacy got today, channel. that in strong X as with a offering know, really type the we've mirrors

the small number at product. say existing and of and the early teams. existing that some moment team we just have we Got they that too like add with to that clinical. need there. of that it of really call capture start can to today started the as it patients to we've But patients, commercial requiring And sales a X So allow the in insulin we're We're we what for primary that for us endocrinology we does think will all with insulin. the XXXX. good an us that does offering physicians It's know we patients to capture for an look as force got Omnipod what on add with coverage. is And a basal-only trial, in DASH. with reside going sales going pod for many It's those indication great getting do do indication care product to model

So come more there. to

that think we'll about does can the it exciting. our to patients It's on primary how we quickly patients then consider that quickly There's doubles how It more think launch that to capturing build in about there. a reimbursement, later probably than they more care how basal-only. reside. just X and start really talk But where I XXXX. TAM, U.S. depend and than are we more in lot with million goes

there's as excited far XXXX. and we as consider to we're So it commercialize about in lot a it, how

Operator

comes line from Jayson James. of the Bedford our question show next I Raymond And from

Jayson Bedford

require that quick questions answers. X Just

submitting not your next few mentioned days, know On on the it's but basal-only FX what's the impact 'XX. guidance, just until think second, but on expected Wayde. then 'XX pod, guidance, And you in I the not I just kidding, commercialization revenue? the

want just selling and why know, gap second, between I is the And big commercialization? XXX(k)? one, So to it a

Wayde McMillan

a color to constant help 'XX here currency before bet. that's providing on basis. Happy the Eric, get the everyone Jayson, that you to about we talk we're guidance,

to And think FX so obviously, going not going to be factoring we where this go at point. is in

currency on know and there don't then a if talk to to think just you about Basel, constant So the color want basis to I

Jim Hollingshead

is XXX(k). Basel, were it we on yes, So submitting it a imminently.

front Just of approvals. in want get a out We on lines time to o. couple don't

for our want don't might we to not consider the saying, done we new that set just There's patient include I points get Bret through. then to on -- be guys an The there's new to It's work offering. do. do know don't need in So offer. built is that Omnipod as is a pod. publicly. call But and core you And points. platform plan. what offering might new, think new. It's reason the a we the commercialization lot call channel that commercial we're work approval the was want as to And it's let We'll the going on a be new-to-world

we we to gun want about have more so talking And jump these don't until certainty. things the on

Operator

show question line from of Oppenheimer. from the Lichtman comes And next I Steve our

Steve Lichtman

being Just point to lower more that can you of different mentioned a device price One, on you do timing maybe relative but follow-ups. you I iOS? two, given apologize that this, a couple into color any channel? you basal-only, of if give COGS a anticipate And as quick go

Jim Hollingshead

with said we're what we'll is IOS, proceeding, last iOS, as in building we're we So quarter, work start that the really confident there.

not on it they're another until and to closer. our had those We've we it. And in update dates talk want Our practice it's to tested don't gun testing teams I as sample about you right jump have That's give our more the one hands. customers. we'll get out of on

our confident to as it can. very is be we're offering but as very quickly going to so get to strong, market we iOS And we want that And

me guys of just the On you -- the basal the say that maybe pod, can maybe -- I'll remind can question

Wayde McMillan

Sure.

not. the and pricing which pricing, we're On

Jim Hollingshead

it same about has different it pod Omnipod is We're the protection. all the IP same based about not talk ready the that it's wrapped about core platform, it say into is because that our it's basal will all What's pricing. IP on to I basal-only.

And experience rate doesn't continuous really to put It's the their it's for do and -- easy I on make the Omnipod, really we're -- to should that. It phobic, very change be here. easy warn huge is has color And into the on potential that anybody the to And has this Look, basal-only it's to and the it's of a going potentially who so then insertion it you right? think or has Is do to benefit daily it is in. beauty to here. to customer what And have lot we're allow fill care on a needle their worked injections and doesn't over extremely it's I and a a XX basal a that's simple disruptive makes picturing what hours. a and huge the to go basal-only for Omnipod get simple that basis because phobia. pod payers. anybody benefit lift I'm it. needle be really take to auto and some to rate can't really really phobia going insertion, it's with going -- there's we to basal want a But with an through. needle therapy give has It controller. built It's just

more closer. get about detail talk you pricing. give to We're going and talk things. not about not to we're guys as going So those COGS We'll we

Operator

Research. of question I the line next our from show comes Pasquale And from Nephron Chris

Chris Pasquale

very about the exciting questions more pod. basal of opportunity. Couple a like sounds It

of talk be benefit lot second, then adoption percentage scratch what basal the like to potential other offering. about more anything is their to each product? Pod in progresses Because talking like sounds insulin here these what any new or B that sensor disease piggyback able have that? to today? of this with reimbursement to it population, rates featured you First, there there's population. titrate the on to as patients focus And CGM start Are need Is this CGM to Omnipod the you're and obviously the coverage patients or from you have on for a going in having

Bret Christensen

patients there as for Yes. far goes. as type between no insulin-intensive difference Chris, is reimbursement great is X and patients question. patients, really the The answer basal basal-only reimbursement to today that

built only in mind. Omnipod basal However, was not with

settings. it some for wasn't so with patients really PDMs, there while using there's complexities are built there's with that basal again, way. And just only, And complexity

to of say, And to look, product. features get it today, a use so have DASH just lot you although of it's if basal-only mealtime going all to the the product effectively a like as program kind and you're to features, a DASH of use we're going rid reimbursed,

basal-only seem to to So not It that does like a do way. ideal a for is what care some pod. physician, wasn't basal-only simply complex built primary they would prescription, that with write which wants

so we on while it And reimbursement is code. it a changing will different plan be because the there,

get will work do just And different it in we're about reimbursed not we price. ready -- so a We We've will talking that. be, at what different a haven't what rate contract confident for. just be talk got that to to before we'll about

them tremendous with to that requires you information CGM physicians' user goes, lift because, and us for know, far As act. as It as CGMs a the the range. provide that's And to going you that's does each a be time shows is complexity pod, other don't but to those really want driving initial because it speak mentioned. product for thinking demand X like basal-only as really valuable for add to our products we

that pod basal-only position on and a thought prescription it. as really as possible. the as We want so keep as is featured a And possible it to to simple write

means And that's we're broad communication and no the to about thinking marketplace. And no That's way best with reports, capture so no what we that settings. think that go today.

Operator

our comes Matthew BTIG. from O'Brien Thibault I comes I question show And Marie next of line of from line question the show our from Sandler. next from Piper the

Marie Thibault

at base In previous point? are that you than mentioned just eventually curious current your think a has Omnipod users what much converted installed on congrats time? what launches. could this And I'm X quarter. portion Omnipod of comments, the at great you convert to converting over higher portion And that

Wayde McMillan

I it's one, Bret Jim jump to Wayde. in. that or can and Marie, I'm then might sure start want

just are that So couple of we here. of the in first full our release, started we're given getting months market just

in the existing seen also we been strong even first just just have in the journey and their well as months So of incredibly MDI we switches to channels, X. conversions coming as Omnipod mentioned competitive all -- tracking has few the Omnipodders them through like

probably And in to these should flow way we're this by going it continue XXXX. as couple customers, these years. of months if strong now the couple trends, be about we really here, XXXX. will of thinking if last But again, of throughout we're right trends in the dynamics they over -- have rates watching the we accelerated So them and with be end majority to of first of many are this converted But is next months conversion or we see these most through continue converting to of we XXXX. after first continue customers do few the different with ebb should the converting the

Operator

line Sandler. from Matthew And our the next Piper of from comes question O'Brien

Matthew O'Brien

Okay. Great.

So to information about that was really of new Marie so up talking a and side well, pump was competitive love think kind is things more on, bit little kind quickly follow because I shift but as the I of would on what startling. the of

Is the next . you're momentum you several that pump over provider drive So the how quarters on of or thoughts the big there? built And continuing of built is the a share space can And it it in legacy into years. then players competitive function that your a being about to throughout both really more the has and quarter? successful? talk

Jim Hollingshead

think no choose. Thanks, Matt. we customers earlier call, need I to said the longer Look, as in

to of forever simplicity we're drawn with the pod elegance And So factor. AID ease customers X, been use Omnipod a of algorithm. a and the form number great offering and have of fantastic

preferred therapy and get channel want, get economics AID factor, the with the to it they they to to so get And want. the form into

people And great economics. clinical The switch so ease easy just and from to tubed offerings. delivers us offering pump of so incredible not use actually outcomes, a it's it see to use of is to and great surprising number

pleased had so switching in rate quarter. And we of we've the were the see -- to

how become or forward tooth to out. as to of it be have think from because might earlier, to will AID who coming they there customers X went that to any -- and plays think customers terms we're offering offer. see wait MDI who I In using appealing Omnipod this wanted the pump going don't less But look, I I either an said the

very offer. we're of confident So robustness in the the

Operator

line Taylor question Jefferies. And our show from next of comes Matt the I from

Unidentified Analyst

been I a guess there's to questions an one. great. which lot wanted the of ask I international looking on U.S., is

evidence to I of that's well the as going could things but Mark, some of coverage. growth your obviously, development few catalysts forward? CE on year was international frame You help there how and mentioned there, just expand those you a to kind you hoping going next expect kind

Jim Hollingshead

of get there's going on on. very So number things the Mark. to CE international, We're a pleased

longer no hurdle have that's a So to get over. we

to X. We Mark, good have for go that's Omnipod CE and

making before, sure we're said what that we terms have of Omnipod delivers the on now that we've in the launch working right cloud right. As X is infrastructure

customers. the you Omnipod If offering think about for X offering, a it's very holistic

also with security be European privacy where experience to markets market launch. So local in full X And sure we to we obviously the we both any with Omnipod have comporting delivering we're data regulations. the and make want and that

being work And do the to so don't talk built. that we RCT that. that's about that's We need

So that if we ex U.S. and clinical as of into those 'XX controlled is in launch we appropriately just and half I Omnipod make right of that evidence markets. we'll U.S., have trial to markets. each have 'XX be those the 'XX for sure in make Omnipod to X The in cascade launch the market randomized a second the designed for ex kind we go we've right -- position we'll to launching then plan second we'll to could middle sure X back Europe as said, be of the stage launches

evidence to pod huge we're to benefit form And and continue AID factor able so a for to of be a non-AID us algorithm for the pumps CGM demonstrate effort X. confident huge emphasis to evidence, against huge that's we're -- that and And a which is build or building where it's our going we're Omnipod alone. for us

Operator

the And Miksic Barclays. from comes of queue line I from our last question Matt show in the

Matt Miksic

really And quarter. on strong a congrats

a tubeless questions of sort and maybe -- couple around color [indiscernible]. comments on Just of

past? If in and essentially if then be in of percentage you mix been coming kind to maybe your on tubeless terms And -- or U.S. And congrats patient the folks or could And elaborate your of staying maybe helpful. just expectations of pump what in some the pump for is if super the with again. that of your color had people as selecting changing that's as diabetes why? changing historically age think color in leaving returning would you after

Bret Christensen

for Matt, thanks question. the

the are we been as MDI, from that So of sort has in always highlighted, we focus. driving leader penetration our and

start the start a new other us, for renewals. don't count And Omnipod starts. on first new shipments. our don't you product. of bulk the So We time We is count an

start has the your And of on where Omnipod, new number been you new focus MDI. where lifetime. MDI, in and starts once has those XX% come XX-XX If have that's always our from, start come from

pediatrics. MDI This the where pumps from had hope a continues. been people we've we came we that bolus quarter, that other leader also only see X And in because of XX% shift the from coming -- we did

I where our about from. think has you're always of been customers our kind Pediatrics strength. asking come

X, form to and where lost were We system. Omnipod an the make that's system very an If to bit you of actually little for that pediatrics to parents attractive factor AID AID parents and again with form the lack perfect the a children. between decision factor about think of forced

to have don't they make Now that.

that. products a lift, So that start life. in to and a new as we for our this newly use them We're lift want significant a pediatrics are we percentage diagnosed quarter. about excited Omnipod want our are did of that Those to starts see patients past on

think coming have we beginning be to about asked about you of as get users. beginning quarter So excited sort excited past this of people And back trend, did Jim to back. And the to Omnipod. people I that the come highlighted of competitive thousands pump call, at see to

the reason. us and left lack AID Likely for an a reason that of. was they So

to that And what existing product. coming X, be so with to does strengthen Omnipod Omnipod with stable, users. we're back about X they're excited retention seen We've and very our attrition

Operator

in like this showing I Hollingshead, Q&A our President remarks. you. would for back Officer, queue. to time, questions Jim session. over concludes the conference turn and At the I'm no closing This to Chief Thank Executive further

Jim Hollingshead

X keeps new and great exciting and could that with market for type as our community for to further and out X basal-only are and with you, execute Thank market us We've Dalam, number diabetes incredibly evening. expand mission. growing. be is thanks, not got thousands on our have continue pod. people, Type times our innovation and of in And for excited transforming to addressable we team, the everyone, today. in Thanks, more a the significant with Omnipod management joining an X incredible our Insulet to These momentum at

Operator

concludes today's call. conference you This you. Thank participating. for Thank

You may now disconnect.

Insulet (PODD) 4 Nov 222022 Q3 Earnings call transcript